This is a prelim inary report ofa new method of treatin g otolaryng ic allergy with enzyme-po tentiated desensitization (EPD). The natu re ofEPD and its use in otolaryngo logy are describ ed. Thirty-six patients have been treated andfo llowed in a private medical p ractice since February 1997. This article reviews the clinical fe atures of EPD and provides six cases as examples; the clinical fe atures described include allergic rhinitis, serous otitis media, asthma, dermatitis. fixed foo d allergy, and Meniere 's disease. EPD is an effec tive techn iquefor the treatm ent of otolaryngi c allerg y and offe rs ad vantages over COl1Ventional techniques.
is currently available in the Unit ed States onl y under an inve stigational protocol approved by the federal Food and Drug Administrati on (FDA) . Thi s article describes the nature of EPD and pro vides examples of its use in otol aryngic allergy.
Methods
Before desensitization therapy is started, it is necessary to establish an accura te diagno sis. Neoplasm s, spec ific infections, diseases, and conditions that are not allergic in natu re must be identified. Only after a clear diagno sis of aller gy has been establis hed by a thorough history , physical examination, and aller gic test ing should immun otherapy be con sid ered .
EPD involves the use of intraderm al injecti on once every 2 month s for 18 to 24 month s. Aft erward , injections are given as required , depending on treatm ent response. The se subsequent injections can be administered as infrequentl y as once every year or even once every 5 years. Each injection in vol ves the use of ultra-low-si zed doses" :" of I,3-diol activator mixed with IOW 6 -IO or ultra-Iow' "" precise doses of specific anti gen . Th e technique invol ves the use of a 0.3-ml insulin syringe with an integral needl e. The syringe contains 0.0 I ml of betaglucuronidase and 0.04 ml of antige n mix for a total volume of intrad erm al injection of 0.05 ml. As many as three antigen mixe s can usuall y be co mbined with a single dose of beta-glucuronidase per injection. Thi s means that a very allergic person requiring multiantigen treatment might need up to thre e separate injections for each treatment. The injections are placed on the forearm 6 inches apart.
Vials containing beta-glucuronidase and anti gen mixes are manufactur ed in England by McEwen Laboratories, Ltd .'" The materials are temperatur e-and time-sensitive and are sent by Federal Express ove rn ight service . They are pack ed in special Styrofoam co ntainers designed to maint ain temperature between 36°and 43°F. The reage nts are kept at those temperatures in a refrigerat or for up to 2 week s while they are used. Because the antigen Is your patie to tell you so • ttymg ething?
Dry mouth due to radiation-induced xerostomia is not only uncomfortable. it can lead to oral health complications. 1 With the longest record of clinically proven efficacy and time proven safety of any prescript ion dry mouth treatment , Salagen Tablets can restore patients ' natural protective saliva. Use of Salagen Tablets is supported by:
• More than 23.000.000 patient-days of therapy'
• Consistent. statistically significant improvements In long-term treatment were two pat ients with un d e~y ing cardiovascular disease of whom one experienced a myocardial infarct and another an episode of syncope. The associationwith drug is uncertain.
Siooren's Syndrome Patients: Incontrolled studies, 376 pat ients received pilocarpine, of whom 5% were men and 95% were women. Race distribut ion was 84% caucasian, 9% Orient al, 3% Bl ack, and 4%01other origin. Mean age was55 yea rs. The majorityof patientswere between 40 and 69 years (70%), 16% were 70 years and older and 14% were youngerthan40years ofage. Ofthese patients, 161/629 (B9I376 receiving pilocarpine) wereovertheageof 65 years.Theadverseevents reported by those over 65 years and those 65 years andyounger were comparable except lornotable trends for uri naryfrequency, diarrhea, and di zziness.The incidences of uri nary frequency and diarrheain the elderly were about doublethoseinthenon-el derly.Theincidenceof dizzinesswas about three timesas high in the elder ly as in the non-elderly. These adverse experiences were not considered to be serious. In the 2 placebo-controlledstudies, the mostcommon adverse event s relatedto drug use weresweating, uri naryfrequency, chills, and vasodilatation (flushing) . The most commonly reported reason for patient disconti nuation oftreatment wassweating. Expect edpharmacologic effects of pilocarpine include the following adverse experiences associated with SAlAGEN' Tablets: Pulmonary Di sease: Pilocarpine has been report ed to increase airway resistance, bronchial smooth muscle tone, and bronchial secretions. Pilocarpi ne hydrochloride should be adminisfered with caution to andunder close medical supervision in patients with controll ed asthma, chronic bronchitis. or chronic obstructive pUlmonary disease requirinq phar mac otherapy.
PRECAUTIONS:
General: Pilocarpine toxi city is characterized by an exaggeration of its parasympafhomimetic effects. These may include: headache, visual disturbance, lacri mation, sweati ng, respiratory di stress, gastrointestinal spasm, nausea, vomiting, diarrhea, atrioventricular block, tachycardia, bradycardi a, hypofension, hypertensi on, shock, mental confusion, cardiac arrhyt hmia,and tremors.
The dose-related cardiovascular pharmacologic effects of pil ocarpine include hypotension, hypert ension, bradycardia, andtachycardia.
Pilocarpineshoul d be admi nistered withcaution to patients with known or suspected cholelithiasis or biliary tract di sease. Contractions of the gall bladder or biliary smooth muscl e could preci pi tate compli cations including cholecystifis, cholangitis,and bili aryobstruction.
Pilocarpine may increase ureteral smooth muscle tone and could
theoreticall y orecpitate renal colic (or "ureteral refl ux"), pa rti c u l a~y in patientswith nephrolithiasis.
Cholinergic agonists may have dose-related central nervous system effects. This should be considered when treating pat ients with unde~ying cognitive or psychiatric disturbances.
Renal Insufficiency: The pharmacokinet ics of orally admi nistered pil ocarpine in pat ient s with renal andhepatic disease is notknown. mixes contain extreme ly small amounts of antigenoften at leve ls simi lar to those found in the environ mentbest results are obtained when the patient avoids unnece ssary expos ure to enviro nmen tal antige ns for several days before and afte r an injection. Most medications sho uld likewise be avo ided aro und the time of injec tion. The EPD antigen mixes that are avai lable and commonly used include IC (high-dosed mixed inhalant s), XE (hig h-dosed mixed alle rge ns) , XO (low -dosed mixed allerge ns [a dilution of XED, terpenes, for maldehyde, P/K C (Proteus/Klebsiella), odds and ends, and detergent s. Additiona l antigen mixes are avai lable for special probl em s; they inclu de woods (desig ned for woo dworkers) , experimental animals (useful for laboratory workers) , and mosquit o.
Use of EPD in otolaryngology
Since Fe bruary 1997, 36 patient s have been on treat ment by the author with EPD on a regular basis. In addition, other physicians' patient s on EPD have been sporadically treated as a convenie nce to them when they are in the Los Angeles area. The followi ng brief case report s are used as exa mples:
Case 1: A llergic rhinitis. A 33-yea r-old man co mplained of nasal obstruction and watery rhi nitis of I year 's dur ation . Testing revealed ex tensive reactions to trees, gras ses , molds, and many foods. Conventio nal imm unotherapy was only partially effective . EPD treatment eve ry 2 month s, beginn ing March 19, 1997, has result ed in exce llent relief of symptoms.
Case 2: A llergic rhinitis. A 59 -year-old white minister had been transferred to Californi a from the Midwest. He co mplai ned of cough, pos tnasa l drip, and recurre nt sinus infections. He had undergone endoscopic sinus surge ry and immunot herapy, but he co ntinued to ex perience recurrent symptoms and episodic sinusitis. EPD therapy was initiated on Feb. II , 1997. After the second series of shots, sy mptoms improved, and the patient has been free of sinus disease and nasal sym ptoms .
Case 3: Serous otitis m edia and asthma. A 49-year-old white wo ma n was refe rred because of rec urren t left otalgia and intractable serous otitis medi a of I year 's dur ation despite the repeated use of antibiotics, placement of ventilating tubes, and the use of oral stero ids. She also co mplained of asthma, and she had had three sinus operations. She complained bitt erly of ear pain with any manipul ation of her ears, and she co uld not tolerate local injection for myringotom y. Wi th ventilating tubes in place, there was a thick meat-like mate rial within the middl e ea r. EPD therapy was initiated on Sep t. 22, 1997 . Continued treatment has led to significant imp rovem ent.
Case 4: A llergic rhinitis, dermatitis, and asthma. A 17-year-old girl had had a rec urrent rash all over her body, Volume 81, Number 3 allergic rhinitis, and asthma for mos t of her life. She had taken predni sone and antihistamines . She was know n to be allergic to seafood. Allergy tests confirmed that she had majo r reactions to seafood, mold s, and trees. EPD therapy was star ted on May 2 1, 1997, and had produ ced co mplete relief until she failed her fourth appointme nt. Treatment was reinstituted on a reg ular basis, and she has been free of symptoms.
Case 5: Fixed food allergy. A 64-yea r-old man had a life-long food allergy to both onion and garl ic. Exposur e to onio n res ulted in the prompt onse t of severe drowsiness that lasted for 2 hours. Exposure to garlic produ ced severe me mory problem s and violent gastroi ntestinal discom fort for 36 hour s. EPD treatm ent has been used reg ularly since March 1997, and it has eliminated these reac tions, other than very mild gas trointes tinal discom fort.
Case 6: Meniere's disease. A43-year-old white woman whose mother and brother were know n to be allergic was troubl ed with bilateral Men iere' s disease, characteris tic of bilateral allergic etiology .
Bilateral endolymphatic subarachnoi d shu nt opera tions and extens ive allergic testin g and immunotherapy in the past had provided only partial co ntro l of fluctuating symptoms. EPD therapy was initiated on Dec. 10, 1997, and discontinued by the patient in February 1998. Treatment has been reg ular since April 13, 1998 . Control has still not been co mplete, but symptoms seem to be less troubl esome.
Discussion
EPD see ms to be a valuable add ition to our abil ity to treat allergic co nditions in otolary ngo logy ." Its pr imary advantage ove r co nve ntional immunoth erapy is its ability to treat antigens not previously treatabl e. In addition, it offe rs effec tive treatment for patient s who are unable or unwilling to be co mpliant in avoidin g kno wn allerge ns .
Th e developm ent ofEPD stemmed from ex perience by Popp er , a Czec h otolary ngo logis t who in 1959 began an experime nt to try to dissolve nasal polyps by injecting them with hyalur onid ase. Th e treatm ent failed to dissolve the polyps, but it seemed to relieve the symptoms of sneezi ng in his allergic patients. By 1962, Pop per discovered that only some batches of hyalu ron idase were active and produced the desired results of desensitization. When he later undertook a pilot trial using a very pur e for m of hyalur oni dase, his patients actu all y did worse .
McEwen in Lond on heard of Popp er' s work and visited him to learn about it firsthan d. McEwen proceeded to test six of the enzy me contaminants in co mmerc ially avai lable hyalu ronidase and discovered the active principl e of beta-glucur oni dase that is now used in EPD. McEwen has worked since that time to define the charac teristics of this techn ique and to crea te extremely pur e antige ns that are y Exmoor Plastics PULEC Serving ENT doctors for 25 years used with the enzy me. In England, EPD is the major method used for immunotherap y, and the technique is available and used routinely throu ghout the world. In addition to treating rhiniti s and hay fever , EPD has been used to treat asthma, eczema, urticaria , angioedema, migraine, bowel disea se, arthritis , psych ological irrit able bowel migraine sy ndro me, attention deficit , autism, and chro nic fatigue immunodeficiency syndrome .
In the Unit ed States, EPD is curre ntly ava ilable to onl y a limited number of physici ans who are participating in a carefully controlled study supervised by the FDA . EPD has not been approv ed by the FDA for general use.
It is not possible to pro vide a complete discu ssion of the diagnosis or treatm ent of allergic disease, nor of all the important aspec ts regarding EPD . But there are several uniqu e aspects of EPD that are of special inte rest and war rant comment. For the average patient complaining of allergies, the initial treatm ent can include the stron ger diluti ons of ant igen . However, pat ient s who are known to have relatively severe allergic reactions or severe asthma sho uld begin with the weaker antigens. It is best to add terpenes at the thi rd treatment because they are more likely to cause a react ion than most of the other antigens. In that way , the ca use of the reaction can be more eas ily determined.
Alth ough no pati ent ha s died from EPD therapy, immunoth erapy inj ec tions can cau se a flar e-up of symptoms . Should a pati ent develop uncomfortable symptoms after an injec tion, the treatment is administration of oral Tofranil (no ge ner ic for m of imipramine is allowed) 25 mg every 4 hour s. Some pati ent s ca n only tole rate 20 mg/day. The do se mu st be drastically redu ced if vertigo or atropin elike side effects occur. For more severe sy mptoms, the treatment is an oral or parenteral steroid. These are the only two age nts that are known to not interfere with the desired immune reaction. Any reaction s usually subside within 4 days. There are five different patterns of respon se to EPD , with early and late relapse s and ea rly and late responses to therapy. In the average patient, treatment pro vides relief within 2 years.
Becau se the en zyme enhances the reac tion to extremely sma ll amounts of antigen, attention mu st be gi ven to the avoidance or eliminati on of potential anti gen s in the env ironment to which the patient is exp osed a few days before and a few days after each injection. In some cases, Candida albicans requires preinjection treatment. Patient s are urged to either fast or ea t a special low-antigen diet consisting of food s that they normally would not eat or a diet restricted to boiled vegetables.
EPD therapy need not replace exis ting methods of immunother apy that have been prov en to be successful. It doe s, however , offer a new dimen sion and an opportunity to treat some patients effe ctively who have not been successfully treated wit h existing tec hniques. In addition, EPD allow s for the treatment of problems pre viously untreatable, such as reactions to fo rmal dehyde , detergents, and perfume (fu mes). It has been show n to effective ly treat fixed food allergies, and it offers great co nvenience fo r the patient with food allergy who does not wis h to co mply and desires to eat in a near-norm al way .
In co ncl usion, EPD is a valuable additio n to our armament arium for the treatm ent of allergic conditions. It is exce ptionally safe, offers co nve nie nce for the patient , and provides effec tive treatm ent fo r antigens previou sly not treatable, such as food s, terp enes, form aldehyd e, Proteus and Klebsiella spp., dete rgents, and a vari ety of dusts, spores, woo ds, and dand ers.
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